Predict your next investment

Angel Investor (Group)
cvilleangelnetwork.net

See what CB Insights has to offer

Investments

16

Portfolio Exits

2

About Charlottesville Angel Network

Charlottesville Angel Network, founded in 2015, is a group of high-net worth individuals, family offices, and successful entrepreneurs who come together on a monthly basis to evaluate start-up company investment presentations in a wide variety of early-stage companies that present high-growth opportunities with a focus on the life science, technology, software, consumer products, and advanced materials fields.

Charlottesville Angel Network Headquarters Location

250 West Main Street Suite 201

Charlottesville, Virginia, 22902,

United States

434-242-5886

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Charlottesville Angel Network News

In Conversation: Kevin Combs, CEO of Molecular Biologicals

Feb 2, 2021

In Conversation: Kevin Combs, CEO of Molecular Biologicals Kevin Combs, the CEO of Molecular Biologicals out of Charlottesville, Virginia, had a front-row seat to the BioHealth Capital Region’s (BHCR) ascendancy. He is now a vital part of the rise of CVille, the life science cluster within the BHCR that is blossoming in and around the University of Virginia (UVA). Combs was recruited to join MedImmune by then CEO Dave Mott , becoming the company’s Executive Director of National Vaccine Sales in 2006. He has gone on to have a highly successful career as a life science executive, a serial entrepreneur, and an angel investor. He is a founding member of the Charlottesville Angel Network (CAN). Combs currently serves as an Entrepreneur in Residence at UVA and is the CEO of Molecular Biologicals, a leading skin and wound care company that is on a mission to transform wound care. Molecular Biologicals has three approved products— KeragelⓇ, KeragelTⓇ, and KeramatrixⓇ, all of which are based on the company’s Keratin molecule platform. We recently caught up with Combs to discuss Molecular Biologicals’ history, vision, and future plans, as well as the excitement and enthusiasm about the CVille bio hub percolating in the region. What are Molecular Biologicals’ origin story and history? The company was founded in 2015. Molecular Biologicals’ origins can be traced back to two companies, Keratac, a company from New Zealand, and Keraplast out of San Antonio, Texas. These companies had both developed a process of removing Keratin from the wool of sheep that contained peptides that could heal wounds. Keraplast had a huge number of Keratin-based patents, and they eventually acquired Keratac, merging the two companies. They tried to run the business in New Zealand but couldn’t get any traction. Eventually, two Keraplast board members decided the U.S. market was a better fit and founded Molecular Biologicals to extract the tremendous value they saw for their IP in the skin and wound care market. I signed on as a consultant in the summer of 2018 to help commercialize and expand the market for the company’s products. That first year my focus was on preparing the market. Then, in 2019, we conducted a clinical use trial that included about 285 doctors using our matrix and gel products. We gathered a lot of very positive data from the trial. By 2020, we were ready to execute our strategy, so I agreed to come onboard as CEO. We knew we needed to raise some cash to execute commercially, so we secured $2M in funding, but then COVID hit and started to really impact us in early April. With elective procedures and Veteran’s Affairs being a big part of our customer base, we had to pivot, and so we turned our attention back to development in May. We moved our manufacturing back to the U.S. and partnered with a U.S. manufacturing firm. The future is characterizing peptides as products with the FDA, not as devices, so we’re actively developing a CMC package for our peptides. Tell us about Molecular Biologicals’ mission and the company’s vision for advancing skin and wound care. Our mission is to provide better products to skin and wound care patients. Patients are our central focus. I’ve always made it a point to work for companies that are driven by patient benefits regardless of profit. “About 30% of chronic wounds just don’t close. Diabetic Foot Ulcers (DFU) are a major challenge. We had a woman that had a chronic DFU that would just not close for over a year. We were able to connect with her through her doctor that was in our clinical use trial, and we learned our product was able to close her wound. That’s what this is all about, that’s the value; we were able to give this woman a better quality of life.” We estimate that the market for chronic wound treatments is somewhere around $6B. That’s a lot of unmet need. We see our annual market potential between $150-$200M. We have the products and the data. Now we need to engage the payers to get our products to more people and to grow the business. What is the science behind the company’s Keratin Platform? There are essentially four phases of wound care, but in the end it comes down to closing the wound from South to North and then from East to West. There are a lot of products that do a good job from South to North but falter during what is called the proliferation stage or going from East to West. This is where our products excel, in the final stage of closing the wound. Our products deliver bioactive keratin to the skin or wound site. This activates keratinocytes, or skin cells, which promote skin cell growth and healing. We have three products, two of which are delivered by a gel (Keragel and KeragelT) and one that is a dressing or matrix (Keramatrix). There are a number of matrix products in the market, but what makes Molecular Biologicals different is that our gels can be self-administered. Unlike a matrix that needs to be applied by a physician, our company’s gel products can be self-administered or administered by caregivers after a wound is debrided by a physician. With COVID, multiple trips to the doctor’s office are very risky, particularly for seniors. After the initial debriding, some patients that use our products won’t have to return to the doctor five or six times; they or their caregiver can deliver treatment at home or at a long term care facility. This also allows physicians to treat more patients given the reduction in the number of visits required to treat a wound. We’ve seen a big uptick in telemedicine and home health care during the pandemic. This is where our gel products are not only highly effective but also reduce other risks posed by multiple visits to the physician’s office. We really feel our products provide great value and can fill a big unmet need. What has it been like growing a business in the Charlottesville biotech/life science community? I’ve been in pharma for 35 or so years. I was at MedImmune in the early days and worked in Cambridge, Massachusetts as well. In 2011, I ran a small pharmaceutical company in Charlottesville and built the company from just a few million into an $85M organization that we sold for a few hundred million. I realized in 2015 that I could stay in Charlottesville and be successful. Charlottesville offers such a great lifestyle and it’s a wonderful place to raise a family. Over the last five or so years, the CVille area has become a legitimate hub, thanks in part to the great work being done by the  CVilleBioHub . Nikki Hastings and her team have really brought the Charlottesville life science community together. There are quite a few high net worth individuals in Charlottesville and a number of investment groups that make CVille a fertile funding environment. There are so many talented people here, including experts in data analytics, pharmacology, as well as some of the top doctors in the world. There’s also a lot of tech transfer opportunities emerging from UVA, which I have some insight into as a UVA Entrepreneur in Residence. In many ways, being in CVille reminds me of my time at MedImmune back when the region was just starting to take off. It seems like that same rising tide lifts all boats mentality exists in Charlottesville as it did in Montgomery County back then. I see the same focus on translational medicine and on moving from the clinic to commercialization. CVille has the financial, regulatory, tech transfer, and talent assets to be something special. The area is starting to spread its wings. What’s next for Molecular Biologicals? We have a well-defined path for moving forward that includes two orphan diseases that will soon be evaluated by the FDA; we could see products emerge for these indications within the next 24 months. We’re also actively exploring other potential products. We expect to raise more funds in 2021 while we will continue to drive the value of our current portfolio by focusing on home health and our self-administered products. The following two tabs change content below.

Charlottesville Angel Network Investments

16 Investments

Charlottesville Angel Network has made 16 investments. Their latest investment was in Dive Technologies as part of their Seed VC on December 12, 2020.

CBI Logo

Charlottesville Angel Network Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/21/2020

Seed VC

Dive Technologies

$4M

Yes

9

4/23/2019

Series A

ChurnZero

$7M

Yes

5

11/28/2018

Angel

ARtGlass

$1.3M

Yes

1

2/12/2018

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

4/1/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/21/2020

4/23/2019

11/28/2018

2/12/2018

4/1/2016

Round

Seed VC

Series A

Angel

Seed VC

Seed VC

Company

Dive Technologies

ChurnZero

ARtGlass

Subscribe to see more

Subscribe to see more

Amount

$4M

$7M

$1.3M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

5

1

10

10

Charlottesville Angel Network Portfolio Exits

2 Portfolio Exits

Charlottesville Angel Network has 2 portfolio exits. Their latest portfolio exit was Dive Technologies on February 02, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/2/2022

Acquired

$99M

4

5/5/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/2/2022

5/5/2021

Exit

Acquired

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

4

10

Charlottesville Angel Network Team

1 Team Member

Charlottesville Angel Network has 1 team member, including current Founder, President, Arthur Watson.

Name

Work History

Title

Status

Arthur Watson

Hyde Park Angels, Babson College, PTC, and Thomas White International

Founder, President

Current

Name

Arthur Watson

Work History

Hyde Park Angels, Babson College, PTC, and Thomas White International

Title

Founder, President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.